In Brief: Novartis
This article was originally published in The Tan Sheet
Novartis: Ciba Geigy/Sandoz merger is one step closer to completion following the approval by the European Commission, the firms announce July 17. The companies are still waiting for approval by U.S. regulatory authorities including FTC and the Justice Department; "substantial progress has been achieved with the FTC," Ciba and Sandoz noted. The firms announced their intention to merge on March 7 ("The Tan Sheet" March 11, p. 1). Fred Huser, current Sandoz U.S. consumer pharmaceuticals president, will head Novartis' U.S. self-medication business ("The Tan Sheet" May 13, p. 6)...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC